CD39 - Amgen

Drug Profile

CD39 - Amgen

Alternative Names: SolCD39

Latest Information Update: 10 Sep 2008

Price : $50

At a glance

  • Originator Amgen
  • Class Antiplatelets; Enzymes
  • Mechanism of Action Enzyme replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cardiovascular disorders; Stroke; Thrombosis

Most Recent Events

  • 10 Sep 2008 Discontinued - Preclinical for Thrombosis in USA (unspecified route)
  • 10 Sep 2008 Discontinued - Preclinical for Stroke in USA (unspecified route)
  • 10 Sep 2008 Discontinued - Preclinical for Cardiovascular disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top